Clinical Development Costs Sample Clauses
Clinical Development Costs. All Clinical Development Costs incurred in accordance with the corresponding Clinical Development Plan budget shall be borne by Athersys and Angiotech in the following proportions:
(a) Clinical Development Costs associated with the execution of any Phase I Study or Phase II Study pursuant to any Clinical Development Plan shall be shared fifty percent (50%) by Athersys and fifty percent (50%) by Angiotech;
(b) Clinical Development Costs associated with the execution of the first Phase III Study conducted pursuant to this Strategic Alliance Agreement shall be shared thirty-three percent (33%) by Athersys and sixty-seven percent (67%) by Angiotech; and
(c) Clinical Development Costs associated with the execution of any Phase III Study that is subsequent to the first Phase III Study trial described in clause (b) above shall be shared twenty-five percent (25%) by Athersys and seventy-five percent (75%) by Angiotech.
Clinical Development Costs. HLBLS shall be responsible for all costs associated with clinical development of Licensed Products undertaken solely in the Licensed Territory. The Parties may agree to collaborate on clinical development under MFDS and other Regulatory Authorities, and costs of such clinical development will be shared on a pro-rata basis calculated by future market share projections.
Clinical Development Costs. ▇▇▇▇▇▇▇ will be responsible for one hundred percent (100%) of all Clinical Development Costs for each Clinical IRD Product; provided, however, that in no event will any Clinical Development Costs for any Calendar Quarter exceed the applicable Clinical Development Budget for such Calendar Quarter, except as otherwise provided in Section 10.3(b). Notwithstanding anything herein to the contrary, in no event [***].
Clinical Development Costs. Except as set forth below or otherwise determined by the Project Team, Lilly shall pay all costs incurred in the Clinical Development Program (including those relating to Regulatory Approvals) after the Effective Date pursuant to the Clinical Development Plan, except those costs involved in conducting those immunology tests described in Exhibit E, which shall be borne by Ophidian. Ophidian shall be responsible for its own costs in providing advice to Lilly.
Clinical Development Costs. Within [***] after receipt of such invoice and report, ▇▇▇▇▇▇▇ will pay to MeiraGTx all the Clinical Development Costs set forth in each such invoice; provided, however, that if the total Clinical Development Costs for such Calendar Quarter exceeds the Clinical Development Budget for such Calendar Quarter, then MeiraGTx will provide written notice to ▇▇▇▇▇▇▇ as far in advance as reasonably possible of such cost overrun along with a reasonably detailed explanation of such cost overrun. ▇▇▇▇▇▇▇ shall pay for such excess only if: (i) the JSC approves of such excess; or (ii) such excess exceeds the Clinical Development Budget for such Calendar Quarter by [***] percent ([***]%) or less and is attributable to (A) a change in Applicable Law, (B) a variation in actual patient enrollment from projected patient enrollment or (C) a change to a clinical trial protocol required or requested by any Regulatory Authority; Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission. provided, however, that in no event will total Clinical Development Costs in any given Calendar Year exceed the Clinical Development Budget for such Calendar Year by more than [***] percent ([***]%), which excess may only be approved by the Parties in writing. ▇▇▇▇▇▇▇ shall not be obligated to pay for any Clinical Development Costs in excess of the Clinical Development Budget except as otherwise set forth in this Section 10.3(b). All such payments of MeiraGTx’s Clinical Development Costs shall be non-creditable and non-refundable. In addition, subject to the terms and conditions herein, if any Clinical Development Plan Activities will exceed the respective portion of the applicable Clinical Development Budget or extend beyond the applicable Clinical Development Plan Term, then (x) MeiraGTx shall provide written notice to ▇▇▇▇▇▇▇, as far in advance as reasonably possible, that MeiraGTx intends to not perform such Clinical Development Plan Activities (with reasonable detail regarding such Clinical Development Plan Activities and Clinical Development Costs), (y) MeiraGTx shall afford the JSC or the Parties, as applicable, a reasonable opportunity to approve additional funding or reimburse such Clinical Development Plan Activities as permitted in this Section 10.3(b), and (z) MeiraGTx shall not be obligated to undertake such Clinical Development Plan Activities unl...
Clinical Development Costs. Except as set forth below or otherwise determined by the Project Team, ************************************** ***************************************************************************.
Clinical Development Costs. Except as set forth below or otherwise determined by the Project Team, [*].
Clinical Development Costs